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Abstract
Over a third of women of childbearing age in the United States are obese, and during pregnancy they are at
increased risk for delayed labor onset and slow labor progress that often results in unplanned cesarean delivery.
The biology behind this dysfunctional parturition is not well understood. Studies of obesity-induced changes in
parturition physiology may facilitate approaches to optimize labor in obese women. In this review, we summarize
known and proposed biologic effects of obesity on labor preparation, contraction/synchronization, and endurance,
drawing on both clinical observation and experimental data. We present evidence from human and animal studies
of interactions between obesity and parturition signaling in all elements of the birth process, including: delayed
cervical ripening, prostaglandin insensitivity, amniotic membrane strengthening, decreased myometrial oxytocin
receptor expression, decreased myocyte action potential initiation and contractility, decreased myocyte gap junction
formation, and impaired myocyte neutralization of reactive oxygen species. We found convincing clinical data on the
effect of obesity on labor initiation and successful delivery, but few studies on the underlying pathobiology. We
suggest research opportunities and therapeutic interventions based on plausible biologic mechanisms.
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Background: The clinical phenotype of labor in
obese women
Over 30% of childbearing age women in the United
States are obese (body mass index [BMI] ≥ 30 kg/m2),
with higher rates among racial and ethnic minority
groups (31.8 % overall, 35.8 % among Hispanic and 55.8 %
among non-Hispanic Black women) [1]. Obesity is associ-
ated with a number of pregnancy complications including
increased risk of gestational diabetes (OR 2.83), gestational
hypertension/pre-eclampsia (OR 2.68) [2], and maternal
depression (OR 1.43) [3]. Maternal obesity also increases
fetal risks for congenital anomalies [4] and macrosomia
(birth weight > 4,500 g) [5], and for lifetime risks of heart
disease [6], diabetes, and obesity [4] as an adult.
The onset of parturition in obese women is frequently
delayed. Without induction, obese women are nearly
twice as likely as normal-weight women to have pro-
longed pregnancy (≥41 weeks gestation), particularly
with BMI of 35 kg/m2 or higher [7–9]. In contrast,
underweight women (BMI < 17 kg/m2) are more than
twice as likely to deliver preterm in spontaneous labor
[10]. Prolonged pregnancy is concerning because there is
a two-fold increased risk of third-trimester stillbirth in
obese women [11]. Interestingly, obese women are also
more likely than normal-weight women to deliver preterm
[12, 13], although 60% of those early births are medically
indicated [13] so the majority of these early deliveries are
likely related to obesity-associated pathology.
During labor, the progress of cervical dilation in obese
women is slower than in normal-weight women [14–17],
a complication known as labor dystocia [18]. In two
large prospective cohorts, increasing maternal BMI had
a clinically relevant dose relationship with protracted
labor (Table 1) [19, 20]. The time to full cervical dilation
in morbidly obese (BMI ≥ 40 kg/m2) mothers was signifi-
cantly longer than normal weight women, regardless of
parity. Even in healthy obese women (without diabetes,
chronic hypertension, or cardiovascular disease) the in-
creased risk for slow cervical dilation (OR 3.9) and
cesarean section (OR 3.2) persists [21]. We found no stud-
ies comparing labor outcomes directly in obese women
with or without obesity-related metabolic dysfunction.
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Obese women are more likely to be admitted to the
hospital at earlier cervical dilation, and to undergo add-
itional intervention to facilitate labor [22, 23], including
administration of synthetic oxytocin (Pitocin; Table 2).
Currently, a standard Pitocin regimen is typically used
regardless of BMI [15] though evidence suggests that
higher median dose and longer duration may be neces-
sary for labor progress in obese women [24]. Despite in-
creased clinical intervention, obese women are two to
three times more likely than normal-weight women to
have unplanned cesarean section (Table 2) [17, 25], a
risk that persists after controlling for obesity-associated
co-morbidities [16, 17]. Post-operative complications are
also more common among obese women, including in-
fection (18.8 % BMI > 45 kg/m2 vs. 7.5 % normal-weight)
[26, 27], postpartum hemorrhage (32.6 % morbidly obese
vs. 4.9 % normal-weight), and prolonged hospitalization
(34.9 % morbidly obese vs. 2.3 % normal-weight) [28].
Reduced gestational weight gain in obese women im-
proves maternal and fetal outcomes in pregnancy, and
the Institute of Medicine has recommended revised pre-
natal care guidelines [29, 30]. Lower weight gain de-
creases the risk of preeclampsia, cesarean delivery, large
for gestational age neonates, and small for gestational age
neonates [29]. There are no data on the safety and out-
comes of intentional weight loss for obese pregnant
women, and that approach is controversial due to con-
cerns for fetal growth and maternal ketosis [31]. In studies
using obese mice, maternal weight loss alters epigenetic
signatures in the offspring [32], emphasizing the need to
understand possible influences of altered prenatal goals.
We need new approaches to improve birth outcomes
in obese women, who have a unique parturition
phenotype [24, 33, 34]. Biologic mechanisms linking
obesity to dysfunctional labor, independent of obesity-
associated comorbidities, are largely unknown. In this
review, we first outline normal parturition physiology and
relevant obesity pathophysiology. We then summarize
studies from human and animal models identifying the
possible molecular basis for differences in labor prepar-
ation, uterine contraction/synchronization, and labor
endurance in obese women. We suggest opportunities for
future investigation, and possible therapeutic targets and
approaches to improve birth outcomes.
Overview of normal parturition physiology
relevant to obesity
Human parturition can be described by myometrial
phases: quiescence, preparation (activation), labor
(contractions), and recovery (involution) [35]. Ninety-
five percent of human gestation is spent in quiescence,
when the myometrium is not contracting and the cervix
is closed. In the preparation phase, the myometrium ex-
presses contractile-associated proteins (CAPs) including
oxytocin receptor (OTR), prostaglandin F receptor, and
connexin-43, and the cervix softens and shortens [36].
In active labor, synchronized uterine contractions dilate
the cervix for delivery of the fetus. In recovery, the uterus
and cervix involute and remodel for future pregnancy.
Specific signals regulate each phase of parturition.
Preparation for parturition
Preparation for parturition is initiated during the final
12 weeks of pregnancy when placental corticotropin-re-
leasing hormone (pCRH) increases dramatically,
leading some investigators to characterize pCRH as a
Table 1 Obese women demonstrate abnormally slow cervical dilation in first stage labor
Number previous vaginal births Study BMI <25.0 BMI 25.0-29.9 BMI 30.0-34.9 BMI 35.0-39.9 BMI ≥40 p value
Zero Kominiarek et al., 2011 [19]
Median 5.4 hrs 5.7 hrs 6.0 hrs 6.7 hrs 7.7 hrs <0.0001
(95 % ile) (18.2 hrs) (18.8 hrs) (19.9 hrs) (22.2 hrs) (25.6 hrs)
Norman et al., 2012 [20]
Median 4.6 hrs 5.0 hrs 5.5 hrs 6.7 hrs <0.01
(95 % ile) (14.4 hrs) (15.7 hrs) (17.3 hrs) (21.2 hrs)
One Kominiarek et al., 2011 [19]
Median 4.6 hrs 4.5 hrs 4.7 hrs 5.0 hrs 5.4 hrs <0.0001
(95 % ile) (17.5 hrs) (17.4 hrs) (17.9 hrs) (19.0 hrs) (20.6 hrs)
Norman et al., 2012 [20]
Median 3.3 hrs 3.9 hrs 4.3 hrs 5.0 hrs <0.01
(95 % ile) (12.6 hrs) (15.1 hrs) (16.5 hrs) (19.2 hrs)
Adjusted duration of labor from 4–10 centimeters cervical dilation by BMI at the time of delivery. Data are median and 95%ile hours in labor
Kominiarek’s median duration adjusted for age, height, race, gestational age, diabetes, induction, augmentation, epidural (first stage), operative vaginal delivery,
and birthweight (N = 118,978)
Norman’s median duration adjusted for induction, race, birth weight > 4,000 g (N = 5,204)
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Table 2 Increased intrapartum interventions and increased risk for cesarean delivery for obese parturients
Intrapartum intervention Study BMI category Odds of use in labor, OR (95 % CI)
Induction of Labor Scott-Pillai et al., 2013 [142] Overweight 1.2 (1.1-1.3)g, h
Obese 1.3 (1.2-1.5)g, h
Obese II 1.4 (1.3-1.6)g, h
Morbid obese 1.6 (1.3-1.9)g, h
Garabedian et al., 2011 [143] Overweight 1.51 (1.42-1.60)a
Obese 2.00 (1.87-2.15)
Obese II 2.36 (2.16-2.58)
Obese III 3.66 (3.30-4.01)
BMI 40–49.9 3.51 (3.15-3.91)
BMI≥ 50 5.25 (3.87-7.10)
Bhattacharya et al., 2007 [9] Overweight 1.3 (1.2-1.4)f
Obese 1.8 (1.6-2.0)f
Morbid obese 1.8 (1.3-2.5)f
Artificial Rupture of Membranes prior to
6 cm cervical dilation
Jensen, Agger, Rasmussen, 1999 [144] Overweight 1.63 (1.18-2.25)g,b
Obese 1.97 (1.20-3.25)g, b
Oxytocin Augmentation of Labor Garabedian et al., 2011 [143] Overweight 1.38 (1.28-1.49)a
Obese 1.87 (1.70-2.06)
Obese II 2.05 (1.79-2.34)
Obese III 3.02 (2.57-3.55)
BMI 40–49.9 3.00 (2.53-3.56)
BMI≥ 50 3.21 (1.97-5.23)
Abenhaim & Benjamin, 2011 [145] Overweight 1.31 (1.15-1.49)g
Obese 1.51 (1.31-1.75)g
Morbid obese 3.05 (1.89-4.94)g
Vahratian, 2005 [146] Overweight Significantly higher use in both categoriesc
Obese
Jensen, Agger, Rasmussen, 1999 [144] Overweight 1.59 (1.22-2.06)f, b
Obese 1.98 (1.28-3.05)g, b
Unplanned Cesarean Delivery Vinturache et al., 2014 [147] Overweight
Spontaneous labor 1.1 (0.6-1.8)
Induced labor 1.2 (0.7-2.0)
Obese
Spontaneous labor 1.5 (0.7-3.0)
Induced labor 2.2 (1.2-4.1)f
Scott-Pillai et al., 2013 [142] Overweight 1.4 (1.2-1.5)g, h
Obese 1.6 (1.4-1.8)g, h
Obese II 1.8 (1.5-2.2)g, h
Morbid obese 1.9 (1.4-2.5)g, h
Green & Shaker, 2011 [148] BMI >35 No sig difference once adjusted for IOLc
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gestational clock [37]. Simultaneously, maternal plasma
CRH binding protein decreases, allowing increased free
pCRH to activate myometrial CRH-receptors that switch
from an isoform that enforces quiescence to an isoform
that activates CAP expression [38]. pCRH also stimulates
fetal pituitary adrenocorticotropic hormone (ACTH) re-
lease, increasing fetal adrenal cortisol production and ma-
ternal myometrial expression of cyclooxgenase-2 (COX-2)
[35]. COX-2 synthesizes prostaglandins (PG) E2 and
PGF2alpha to promote myometrial activation. Fetal cortisol
increases placental pCRH production in a feed-forward
loop that stimulates fetal production of dehydroepiandros-
terone (DHEA) which is converted to estriol by placental
enzymes [39]. Estriol, the dominant placental estrogen,
increases myometrial sensitivity to oxytocin and PGs,
and stimulates oxytocin release from choriodecidual
tissues [40].
In humans, progesterone does not decline dramatically
at term, but serum progesterone increases at a slower
rate while estradiol or estriol production accelerates,
leading to an elevated estrogen to progesterone ratio.
These changes are sometimes characterized as functional
progesterone withdrawal [35]. Further, and perhaps
more important, progesterone receptor (PR) expression
changes from a predominance of PR-B to more PR-A
receptors [35], thereby activating a different set of genes
[41]. PR-B mediates the primary pro-gestational (i.e.,
quiescence) function of progesterone while the truncated
Table 2 Increased intrapartum interventions and increased risk for cesarean delivery for obese parturients (Continued)
Garabedian et al., 2011 [143] Overweight 1.44 (1.38-1.50)g
Obese 1.96 (1.86-2.06)g
Obese II 2.32 (2.17-2.47)g
Obese III 3.66 (3.39-3.95)g
BMI 40–49.9 3.53 (3.26-3.82)g
BMI≥ 50 4.99 (4.00-6.22)g
Abenhaim & Benjamin, 2011 [145] Overweight
1.07 (0.80-1.43)dObese
Morbid obese
Cedergren, 2009 [149] Overweight 1.09 (0.91-1.31)
Due to obstructed labor Obese I 1.56 (1.14-2.14)f
Obese II 1.33 (0.72-2.46)
Morbid obese 1.79 (0.65-4.92)
Cedergren, 2009 [149] Overweight 1.50 (1.42-1.59)g
Due to ineffective uterine contractility Obese I 2.14 (1.96-2.34)g
Obese II 2.72 (2.35-3.16)g
Morbid obese 3.98 (3.14-5.04)g
Bhattacharya et al., 2007 [9] Overweigh 1.5 (1.3-1.6)f
Obese 2.0 (1.8-2.3)f
Morbid obese 2.8 (2.0-3.9)f
Sukalich, Mingione, Glantz, 2006 [150] Obese 1.07 (1.05-1.09)f
Vahratian, 2005 [146] Overweight 1.2 (0.8-1.8)f, e
Obese 1.5 (1.05-2.0)f
Jensen, Agger, Rasmussen, 1999 [144] Overweight 1.69 (1.06-2.68)f, b
Obese 1.91 (0.94-3.86)b
Updated from Carlson & Lowe [111]. Odds ratios are for comparison with women of normal BMI
aSignificance not computed
bOR and CIs calculated from frequency tables provided in manuscript
cOR and CI not provided
dNot significant when adjusted for known confounders (maternal age, parity, previous c/s, DM, GDM, hypertension, preeclampsia, cervix on admit, IOL, birthweight,
gestational age) and for labor management differences (use of epidural analgesia, oxytocin, forceps, vacuum)
eAdjusted risk ratio reported
fSignificant at p < .05
gSignificant at p < .001
hAdjusted for age, parity, social deprivation, smoking, and year of birth
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N-terminal of PR-A prevents recruitment of coactivators
and alters myometrial progesterone gene activation.
Thus, the PR isoform switch reduces progesterone’s
pregnancy maintenance function and facilitates the mo-
lecular program leading to myometrial contractility.
Other factors suggested to modulate the myometrial
labor program include epigenetic regulation of pCRH
gene expression [42], NFkappaB inflammatory blockade
of PR responsive genes [43], recruitment of inflamma-
tory macrophages to the myometrium [44], and per-
haps increased cell-free fetal DNA in the maternal
circulation [45].
The cervix shortens and ripens for several weeks be-
fore labor in response to PGE2 and PGF2alpha, released
by fetal membranes [35]. Cervical extracellular collagen
disperses, water content increases, and fibrous stroma
degrades. Matrix metalloproteinases (MMPs), released
by cervical stromal fibroblasts and smooth muscle cells,
break down cervical stromal proteoglycans [46, 47]. In
addition, cervical epithelial and stromal cells undergo
apoptosis, decreasing the cellular content of the laboring
cervix [48]. The amnion and chorion overlying the in-
ternal cervical os degrade before labor, with increased
apoptosis leading to rupture of membranes [49]. Disrup-
tion of fetal membranes releases amniotic fluid that ex-
poses decidua and myometrium to PGE2 and oxytocin,
enhancing labor activation [35].
Contraction & synchronization in parturition
Phasic uterine contractions are a hallmark of active
labor, accompanied by progressive cervical dilation. Indi-
vidual myocytes contract when actin and phosphorylated
myosin interact via ATP-consuming cross-bridge cyc-
ling [50] triggered by increased intracellular calcium
ion (Ca2+). Prior to parturition, Ca2+ efflux and intra-
cellular sequestration lead to decreased intracellular
Ca2+ and myocyte relaxation. Low resting Ca2+, along
with potassium (K+) channel opening and plasma
membrane repolarization promote the quiescent state.
During labor, myosin phosphorylation is initiated by
myocyte depolarization leading to calcium influx, pri-
marily via L-type Ca2+ channels. Oxytocin signaling via
the oxytocin receptor (OTR) promotes more frequent and
forceful uterine contractions and release of PGs from the
decidua [35, 51]. The posterior pituitary releases pulsatile
oxytocin, and decidual and placental tissues produce oxy-
tocin continuously [35, 52]. During late gestation, OTRs
increase sharply in the myometrium and decidua as the
primary mediator of oxytocin response in labor. The basic
biology of myocyte contractility has been reviewed in
detail elsewhere [35, 50, 53, 54].
During labor, myocyte contraction is coordinated,
starting in the uterine “pacemaker” at the fundus and
spreading toward the cervix [55, 56]. Neighboring
myocytes become connected via plasma membrane gap
junctions that assemble immediately before labor [57].
These low-resistance pores formed by connexins (e.g.,
connexin-43), allow action potentials to travel freely
from cell to cell, transforming the uterus into a func-
tional syncytium [58]. Stronger and longer originating
action potentials result in organized uterine contractions
of increasing force [59, 60].
Uterine endurance in parturition
During labor, the uterus must maintain sufficient
strength and duration of contraction, or endurance, to
expel the fetus and maintain postpartum hemostasis.
During contractions, ATP hydrolysis releases protons,
producing transient acidification [50]. Forceful contrac-
tions occlude blood vessels in the uterine wall, causing
repetitive ischemia and reperfusion that leads to periodic
acidification due to anaerobic lactic acid production
[50, 61]. Cyclic hypoxia/reperfusion also produces re-
active oxygen species (ROS) [62]. Myocyte regulatory
mechanisms counteract the lower pH (e.g., hypoxia-
resistant lactate dehydrogenase isoform) and elevated
ROS (e.g., Glutathione Peroxidase [GSHPx]), main-
taining labor endurance [50, 63].
Overview of obesity physiology relevant to
pregnancy
Nearly 70 % of obese patients exhibit metabolic dysregu-
lation with changes in circulating hormones [64–66] and
free fatty acids (FFA). For this reason, obesity results in
altered physiology that may influence normal parturition
pathways.
Circulating molecules in obesity
Increasing BMI alters the secretion of a range of hor-
mones from adipose tissue. Highly relevant to pregnancy
is leptin, an adipokine secreted primarily by white adi-
pose tissue. Leptin suppresses appetite, stimulates adipo-
cyte hypertrophy, and increases FFA oxidation [67, 68].
Free leptin rises with BMI and increased adiposity, but
obese individuals also exhibit impaired satiety feedback.
This “leptin resistance” may be the result of chronic in-
flammatory mediators that disrupt normal hypothalamic
homeostasis [67, 69, 70]. The placenta also secretes lep-
tin [67, 71], peaking in the second trimester. Leptin is
significantly increased in obese compared to normal-
weight pregnant women [72]. In contrast, soluble leptin
receptor decreases linearly with increasing BMI in preg-
nancy, leading to high serum free leptin in obese preg-
nant women [67].
Four other adipokines may be of importance. Apelin,
secreted by adipose tissue and placenta [73, 74], is ele-
vated in obese pregnant women and associated with
insulin resistance [75]. Physiologically, apelin causes
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hypotension, regulates fluid homeostasis intake, and is
produced in response to insulin release [73]. Visfatin in-
creases in pregnant women near labor [76]. Visfatin is
highly expressed by visceral adipose cells, and activates
insulin receptors. Ghrelin, in contrast, is inversely re-
lated to maternal BMI. It stimulates insulin secretion,
and regulates food intake and fat utilization during preg-
nancy [77, 78]. The most abundant adipokine is adipo-
nectin, which regulates energy metabolism by increasing
glucose uptake, lipid catabolism, and insulin sensitivity
[79]. Adiponectin is decreased among pregnant women
with higher BMI and those with more pronounced
dyslipidemia [80].
Plasma cholesterol increases with obesity and also in
pregnancy. Plasma lipids and lipoproteins increase
throughout pregnancy, supplying nutrients to the fetus
and supporting fetal cholesterol biosynthesis [80]. In re-
productive age females, hypercholesterolemia increases
with BMI beyond that associated with normal pregnancy
[81]. Perhaps more importantly, obese insulin resistant
women (i.e., more metabolically dysfunctional) show a
shift to an atherogenic lipoprotein phenotype, including
increased plasma triglycerides and small low density
lipoproteins (LDL) [80, 82], that is associated with gesta-
tional diabetes [83], ectopic fat deposition [84], and ath-
erosclerosis [85].
Obesity also alters vitamins, minerals, and cofactors.
For example, low vitamin D levels are found more often
among obese and overweight individuals, and associated
with chronic disorders like cardiovascular disease and
diabetes [86]. Low folic acid levels are similarly linked to
obesity, resulting in increased neural tube defects in
offspring of obese women [87].
FFA storage and meta-inflammation
In pregnancy, obese women have higher triglyceride and
FFA levels than normal-weight pregnant women. When
FFA levels overwhelm adipocyte storage capacity, excess
FFA is sequestered as triglyceride in new adipocytes or
within fat droplets in non-adipose tissues (ectopic fat)
[65]. As FFA levels increase further, they may circulate
and be used instead of glucose for cellular metabolism
[88]. Mitochondrial lipid metabolism produces ROS that
can damage cellular structures and impair insulin re-
sponses, a process called lipotoxicity. Normally, cells
neutralize ROS with cellular antioxidants, but with in-
creased FFA, that capacity is overwhelmed, and ROS
cause RNA/DNA damage, protein carbonylation, and
eventual apoptosis [63, 89, 90]. ROS-mediated cell dam-
age releases inflammatory mediators (e.g., interleukin-6,
interleukin-1ß, tumor necrosis factor-α), creating
chronic low-grade inflammation throughout the body
known as meta-inflammation [91, 92], which further
increases ROS production [90].
Insulin is crucial for glucose uptake, glycogen synthe-
sis, lipogenesis, and cell growth, and stimulates adipose
uptake and storage of FFA [93]. Insulin resistance is nor-
mal in human pregnancy, a necessary adaptation to en-
sure appropriate maternal nutrient shunting to the fetus
[94]. As insulin resistance exacerbates the FFA storage
problem, pregnancy may worsen obesity-related ROS
damage and meta-inflammation [93].
Methods: a literature search for interactions
between obesity and parturition signaling
Considering the known physiology described above, we
explored the experimental evidence for interactions be-
tween the physiology of obesity and normal parturition
signaling. Our primary question was: What biologic
mechanisms could be responsible for parturition dys-
function in obesity? In June 2015, we performed a com-
prehensive literature review using PubMed, Google
Scholar, Web of Science, and MEDLINE databases with
the primary medical subject heading (MeSH) search
terms: obesity, labor, parturition, and pregnancy. Add-
itional search terms included: BMI, uterus, myometrium,
dystocia, mechanism, and dysfunction. We considered
all original research in the English language from any
year. We also considered relevant articles from citations
in these publications. After initial screening, we obtained
full-text articles for evaluation of content, quality, and
relevance and included all studies relevant to potential
interactions between physiologic changes of obesity and
dysfunctional labor (Additional file 1: Table S1).
Review of evidence: biologic mechanisms of labor
dysfunction in obesity
We identified 31 studies for review (Additional file 1:
Table S1) and have grouped them into three categories:
labor onset, contraction/synchronization, and endur-
ance. They include human, animal, and cell culture
studies. Figure 1 summarizes interactions between obes-
ity and parturition. Some mechanisms were corrobo-
rated by multiple investigators, while others involve only
early work and suggested hypotheses.
Changes in labor preparation due to obesity
Placental function
Obesity increases placental weight and hypertrophy, but
reduces the fetal/placental weight ratio (sometimes re-
ferred to as “placental efficiency”) [95]. A high fat diet
decreases uterine blood flow, potentially leading to pla-
cental relative hypoxia and trophoblast dysfunction [96].
Placental amino acid transport is reduced in women
with normal birthweight infants [97], but increased in
obese mice [98] and in women with large babies [99].
Altered placental steroid hormone biosynthesis in obese
pregnant women has not been established, but obesity
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is associated with lower mid- and late-pregnancy
pCRH [100, 101]. Decreased pCRH together with
changes in placental structure/function could alter
estrogen/progesterone production, metabolism, or ra-
tio resulting in delayed onset of parturition [102]. We
found no studies on the changes in placental partur-
ition steroid hormone signaling with obesity that
might account for altered parturition timing.
Elevated leptin
Leptin stimulates PGE2 release from placental and adi-
pose tissue via inflammatory signaling pathways [103].
Chronically elevated PGE2 in late pregnancy among
obese women with meta-inflammation could decrease
the sensitivity of maternal tissues to PGE2 during labor
activation, a finding that has been documented clinically
[104] and is supported by the known elevated PGE2 in
obesity [105, 106]. Insensitivity to PGE2 during labor in-
duction is linked to failed functional progesterone with-
drawal [107]. Thus, the chronic inflammatory state of
obese women could impede functional progesterone
withdrawal and PGE2 activation. There is no current evi-
dence examining changes in myometrial PRB/PRA
switching with obesity.
Leptin also disrupts in vitro collagen degradation by
MMPs, as well as cervical cell apoptosis [108, 109], two
effects that may inhibit cervical ripening in obese
women. Further, leptin stimulates cervical collagen syn-
thesis in late pregnancy [108, 151], possibly explaining
the decreased cervical ripening at term in obese women
that we see clinically [110]. High circulating leptin in the
second trimester may also inhibit fetal membrane weak-
ening through decreased membrane apoptosis [109],
thereby inhibiting spontaneous rupture of membranes in
obese women [49]. The clinical finding that there is an
increased requirement for artificial rupture of mem-
branes with increasing BMI supports this hypothesis
(Table 2) [111].
Changes in labor contraction/synchronization due
to obesity
Adipokines
Leptin exerts an inhibitory effect on spontaneous and
oxytocin-stimulated myometrial contractions in vitro
[112] however, the second trimester serum leptin level
does not explain the risk of failed first-stage labor in an
adjusted model [113]. To our knowledge, there are no
published reports on labor outcome related to third-
trimester leptin levels. Visfatin also decreases both spon-
taneous and oxytocin-induced contractions [76]. There
are no data on whether adiponectin influences myome-
trial contractility [114]. Apelin also inhibits spontaneous
and oxytocin-induced myometrial contractions in organ
bath, but has not been evaluated clinically [73]. Ghrelin
may stimulate myometrial contractions [114], although
there are conflicting reports [78].
Cholesterol
Cholesterol supports plasma membrane channel func-
tion in cholesterol-rich “lipid rafts” [115]. Smooth
muscle cells, including myocytes, are rich in a particular
type of lipid raft, the caveolae [116], on which potassium
Fig. 1 Overview of Obesity-Related Biologic Dysfunction of Labor. PGE2 = prostaglandin E2 (dinoprostone; naturally occurring prostaglandin). Blue
italicized script = Proposed mechanism or mechanism with limited evidence
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channels such as Maxi-K and human ether-a-go-go–
related gene (hERG) K+ channels cluster [60, 117].
These hyperpolarizing, and therefore pro-relaxant
channels, are more active with the hypercholesterol-
emia that is more common among obese than normal-
weight women. Both estrogen receptors [118] and
oxytocin receptors [119] associate with myocyte mem-
brane caveolae, but it is unknown whether maternal
hypercholesterolemia alters the stability or function of
these receptors. Cholesterol and LDL reduced con-
traction force and frequency in human and rodent
myometrial strips, effects that were not alleviated by
exogenous oxytocin [120, 121]. Mice with dysfunc-
tional hepatic cholesterol clearance exhibited reduced
oxytocin responses and abnormal labor without pup
expulsion [122]. In humans, elevated maternal choles-
terol at 14–16 weeks gestation is not a risk factor for
first stage labor dystocia leading to cesarean section
[123]. We found no studies that evaluated labor pro-
gress or outcomes by maternal cholesterol or mater-
nal triglyceride levels near the time of birth.
Oxytocin receptors (OTR)
Obese women require more Pitocin for labor induction,
even controlling for neonate size, parity, and epidural
anesthesia [33, 124, 125]. Existing reports on obesity-
dependent changes in OTR are contradictory [152]. In
one study, OTR mRNA was decreased in myometrial bi-
opsies from term pregnancies in women with higher
BMI at delivery [126], but another group found no
change in OTR gene or protein expression with in-
creasing BMI [127], though greater than 30% of those
subjects were laboring. Biopsy location, timing in
pregnancy, and stage of labor could all influence OTR
results [51], and women with protracted labor and
delayed transition to active labor have different OTR
gene polymorphisms than those with efficient labor
[128]. Thus, labor progress is demonstrably sensitive
to OTR expression, suggesting the important question
of whether altered OTR is in part responsible for de-
layed labor in obese women. Genome-wide associ-
ation studies have not evaluated interactions between
obesity, OTR, and labor outcomes.
Gap junctions
We found no human studies investigating uterine
connexin-43 expression in obesity or with labor dystocia.
Uterine biopsies from a mixed-weight sample of women
with prolonged labor have decreased connexin-43
mRNA compared to normal labor [58]. Rats fed a high-
fat, high-cholesterol diet during pregnancy showed
significantly lower connexin-43 expression compared to
animals eating regular chow, although contractility was
not examined [129].
Changes in uterine endurance in labor due to obesity
Women with slow labor have lower oxygen saturation, in-
creased myometrial lactate, and more acidic capillary pH
compared to normal controls (pH 7.35 in dysfunctional
labor vs. 7.48 in normal labor) [130]. One labor dystocia
theory posits that lower pH and increased ROS cause
unorganized and ineffective contractions, and an individ-
ual’s capacity to buffer pH and neutralize ROS predicts
labor dystocia [130]. It is possible that obesity-related lipo-
toxicity when combined with normal myometrial ROS
production during labor leads to excess ROS that might
cause labor dystocia. Increased pre-pregnancy BMI is as-
sociated with excessive placental ROS and decreased ATP
production [131]. However, high-fat/cholesterol diet did
not change term non-laboring rat myometrial mitochon-
drial function [132]. We found no evidence for changes in
myometrial cellular respiration, ROS with obesity, or
effects of either on labor endurance.
Discussion
In a theoretical model of successful human parturition,
labor occurs as a result of “integrative and synergistic
coordination” of separate biological processes or mod-
ules, occurring across many tissues [133]. With obesity,
the delayed labor and labor dystocia phenotypes could
result from multiple accumulated parturition malfunc-
tions (Fig. 2) in the placenta, cervix, amnion, and myo-
metrium. Obesity may also decrease labor endurance,
with meta-inflammation and excess FFA causing excess
myometrial ROS accumulation. Changes in biologic sig-
nals or responses with obesity could alter the onset,
synchronization, and endurance of labor. Our literature
search identified several questions that require additional
basic and translational investigation, and as the effects of
obesity are better understood, additional hypotheses will
likely be generated. Considering the evidence for the
pathobiology of labor dystocia in obesity, we suggest sev-
eral investigative and therapeutic opportunities to im-
prove vaginal delivery rates:
 Basic science investigation: We have summarized the
existing evidence that obesity produces important
changes in parturition signaling and the molecular
program of labor in placenta, myometrium, and
cervix. It is clear that each known step in the
parturition process could be altered by hormones
or other unique regulation produced by adipose
tissue or associated meta-inflammation. However,
we need to identify specific mechanisms.
o It will be important to define the type of
estrogens (estriol or estradiol) produced in
obese parturients and the effect of obesity on
the ratio of estrogen to progesterone at term. In
addition, the effect of obesity on placental
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hormone production and myometrial progesterone
receptor expression must be quantified in both
animal models and women if we are to develop new
approaches to modifying the deleterious effects of
obesity.
o Preclinical animal models of obesity management
in pregnancy, for example limited weight gain and
intentional weight loss, may reveal important
parturition and fetal effects.
o Basic investigation of whether increased fat
mass alone or associated metabolic syndrome
and meta-inflammation drive parturition
dysfunction is warranted. Metabolomic
characterization of obese women with labor
dystocia or Pitocin resistance could further
our understanding of the signals linking obesity
and labor outcome versus the separate influence
of metabolic syndrome.
 Clinical management: Allowing additional time
for obese women to complete cervical ripening
and the first stage of labor before proceeding to
cesarean delivery for slow labor progress could
immediately improve outcomes [134, 135]. Clinical
tools to identify aberrant labor progress with obesity,
such as BMI-determined labor partograms, are
needed. Further, investigating parturition changes
with decreased weight gain or weight loss during
obese pregnancy may be informative. The safety
and outcome of altered prenatal and obstetric
management requires thorough clinical evaluation
and prospective trials [136].
 Medication management: Obese women may benefit
from optimized protocols for Pitocin (and other
induction/augmentation agents), rather than the
universal protocols currently in use for women of
any BMI. Higher doses and/or longer infusion times
may be necessary for induction of labor in an obese
woman. The differences in OTR expression and
function and myometrial contractility between obese
and normal-weight women are not yet defined. All
induction agents may need to be examined to find
the most effective regimen for obese cohorts.
Fig. 2 Comparison of normal and obesity-associated mechanisms of labor. MMP =matrix metalloproteinase, hERG K + =human ether-a-go-go-related
gene potassium channel, pCRH= placental corticotropin releasing hormone, FFA = free fatty acid, ROS = reactive oxygen species, GSHPX = glutathione
peroxidase, OTR = oxytocin receptor, PGE2 = prostaglandin E2, connexin-43 =myometrial gap junction. Blue italicized script = proposed mechanism or
mechanism with limited evidence
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 Therapeutic investigation:
o Cholesterol-lowering therapies (e.g., statins,
niacin, bile acid sequestrants) might prevent
hypercholesterolemia-linked suppression of
contractions in obese women. Although statins
are rated Category X in pregnancy, the
teratogenic potential appears to be limited to
extraordinarily high doses in animal models,
and in select cases the potential benefits may
outweigh the risks, even during pregnancy
[137]. Randomized controlled trials (RCT) are
needed.
o Thiazolidinedione (TZD) activates peroxisome
proliferator-activated receptors (PPARs), allowing
for safe storage of FFA, improved insulin
sensitivity, and decreased cellular ROS damage
[138]. Activation of the PPAR system is known to
reduce recruitment of immune cells and inhibit
inflammation, allowing better utilization of
glucose as an energy source for cellular
processes [65]. TZD therapy could improve
labor endurance by decreasing myometrial
ROS damage from FFA metabolism, although
the known association of TZD with increased
weight gain [139] could carry other risks. A RCT
of TZD therapy to improve labor endurance is
needed.
 Nutrition intervention:
o High-fat diet apparently decreases uterine blood
flow [96] and lowers connexin-43 expression
[129] in animal models. Prospective investigation
of the effect of dietary fat in normal and obese
women on labor length, induction response, and
dystocia incidence is needed.
o Serum vitamin D is inversely related to both
visceral and subcutaneous fat and insulin
resistance [140], and significantly decreases
biomarkers of oxidative stress [141]. A RCT
investigating nutritional supplementation of
anti-oxidants (e.g., vitamins D, C, E, and
DHA/EPA) to modulate lipotoxicity-linked ROS
elevation and improve labor outcomes is needed.
Conclusion
Obesity is associated with changes in the placenta,
cervix, amnion, and myometrium that could alter labor
preparation, contraction/synchronization, and endur-
ance. Studies investigating the biologic mechanisms of
labor dystocia and failed induction due to obesity, both
basic and translational, are needed. With a better under-
standing of the unique biology of obese parturients, we
may develop better techniques and treatments to
optimize labor outcomes, increase the rate of vaginal de-
liveries, and reduce the risk of obstetric complications.
Even without new medications, changing our clinical
management of obese women offers an immediate op-
portunity to decrease unplanned cesareans. Simply offer-
ing additional time in labor for obese women could
result in increased vaginal deliveries. Therefore, while
initial efforts to address obesity-related labor dysfunction
could be directed to clinical management, future inter-
ventions can be designed to correct or overcome the
altered parturition physiology in obese women. More-
over, as additional molecular details of human partur-
ition are discovered, there may be substantial benefit to
exploring the interactions with obesity. As obesity in-
creases in the population, addressing the interactions
between obesity and normal physiology is a women’s
health priority, and may lead to important improve-
ments in obstetric care and the well-being of mothers
and their newborn children. For now, we suggest giving
more time clinically to circumvent the parturition dys-
function in obesity, while we invest additional time and
research in understanding better the pathobiological
effects of obesity on normal parturition signaling.
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